|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM394487648 |
| 003 |
DE-627 |
| 005 |
20251025232344.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
251025s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2025.110610
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1609.xml
|
| 035 |
|
|
|a (DE-627)NLM394487648
|
| 035 |
|
|
|a (NLM)41130331
|
| 035 |
|
|
|a (PII)S1521-6616(25)00185-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Brevet, Pauline
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Autoantibody fine specificity restriction is associated with clinical response in RA treated with abatacept and methotrexate
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 23.10.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a Copyright © 2025. Published by Elsevier Inc.
|
| 520 |
|
|
|a OBJECTIVE: Anti-modified protein antibodies (AMPA) are central in rheumatoid arthritis (RA). We evaluated whether changes in fine specificities (FS) of anti-citrullinated protein antibodies (ACPA) and anti-CarP antibodies relate to clinical prognosis in RA patients treated with abatacept (ABA) plus methotrexate (MTX)
|
| 520 |
|
|
|a METHODS: A multiplex bead immunoassay measured 6 ACPA FS and 1 anti-CarP FS in 59 anti-CCP+ RA patients (IgG, IgA). Disease activity (DAS28-CRP) and FS levels were assessed at baseline (M0) and 6 months (M6)
|
| 520 |
|
|
|a RESULTS: After 6 months of ABA+MTX, several FS decreased with frequent negative seroconversion (NS). Higher baseline anti-citrullinated α-enolase (ACit-ENO1) IgG levels predicted better outcome (decrease of -0.17 DAS28 score per decile, 95 % CI -0.27 to -0.07, p = 0.03). Among patients with ≥1 positive FS at M0, a higher number of NS across 14 FS (IgG/IgA) correlated with greater improvement (-0.27 DAS28 score per antibody, 95 % CI -0.39 to -0.15, p < 0.0001)
|
| 520 |
|
|
|a CONCLUSIONS: In this cohort of limited size, clinical response at M6 with ABA+MTX treatment was associated with the restriction of the autoantibody repertoire of IgG and IgA classes in RA patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a ACPA
|
| 650 |
|
4 |
|a Anti-CCP
|
| 650 |
|
4 |
|a Anti-CarP
|
| 650 |
|
4 |
|a Disease activity
|
| 650 |
|
4 |
|a Fine specificities
|
| 650 |
|
4 |
|a IgA class
|
| 650 |
|
4 |
|a Prognosis
|
| 650 |
|
4 |
|a Rheumatoid arthritis
|
| 700 |
1 |
|
|a Gillibert, André
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Le Goaréguer, Léna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lattard, Claire
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Drouot, Laurent
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Varin, Rémi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Golinski, Marie-Laure
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Candon, Sophie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boyer, Olivier
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lequerré, Thierry
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vittecoq, Olivier
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fréret, Manuel
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g (2025) vom: 21. Okt., Seite 110610
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g year:2025
|g day:21
|g month:10
|g pages:110610
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2025.110610
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2025
|b 21
|c 10
|h 110610
|